These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31425908)

  • 1. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
    Hirota T; Muraki S; Ieiri I
    Clin Pharmacokinet; 2019 Apr; 58(4):403-420. PubMed ID: 29915924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
    Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
    Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
    Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
    J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
    Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
    JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
    Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H; Lai L; Wu B
    Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.
    Perera S; Piwnica-Worms D; Alauddin MM
    J Labelled Comp Radiopharm; 2016 Mar; 59(3):103-8. PubMed ID: 26853088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-[
    Buck JR; Saleh S; Claus T; Lovly C; Hight MR; Nickels ML; Noor Tantawy M; Charles Manning H
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127257. PubMed ID: 32631505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
    Zhao Z; Bourne PE
    J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.